表紙:トゥレット症候群(中枢神経系):開発中の薬剤(2021年)
市場調査レポート
商品コード
1000821

トゥレット症候群(中枢神経系):開発中の薬剤(2021年)

Tourette Syndrome (Central Nervous System) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 74 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
トゥレット症候群(中枢神経系):開発中の薬剤(2021年)
出版日: 2021年03月31日
発行: Global Markets Direct
ページ情報: 英文 74 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

トゥレット症候群(TS)は、チックと呼ばれる反復的で固定観念的な不随意運動と発声を特徴とする神経障害です。症状には、まばたきやその他の目の動き、顔のしかめっ面、肩をすくめる、頭や肩のけいれんなどがあります。その他の症状には、鼻に触れる、物の匂いを嗅ぐ、腕をバタバタさせる、ホッピングするなどが挙げられます。病因には年齢が挙げられ、男性は女性の約3~4倍発症しやすいと言われています。治療には、抗うつ薬、精神刺激薬、行動療法などがあります。

当レポートは、トゥレット症候群(中枢神経系)の開発中の薬剤について調査しており、世界の治療情勢、パイプライン治療法のレビュー、開発、パイプライン製品の薬剤プロファイル、主要企業のレビュー、トゥレット症候群の治療に関する最新ニュースなどの包括的な情報を提供しています。

目次

  • イントロダクション
  • Global Markets Directのレポート範囲
  • トゥレット症候群-概要
  • トゥレット症候群-治療法の開発
  • パイプラインの概要
  • 企業別パイプライン
  • 大学/機関別パイプライン
  • 企業が開発中の製品
  • 大学/機関が開発中の製品
  • トゥレット症候群-治療評価
  • ターゲット別評価
  • 作用機序別評価
  • 投与経路別評価
  • 分子タイプ別評価
  • トゥレット症候群-治療法開発に関与する企業
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • トゥレット症候群-薬剤プロファイル
  • アルファ-ジヒドロテトラベナジン-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • ベバントロール-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • デュテトラベナジン-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • ドロナビノール+パルミトイル-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • 塩酸エコピパム-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • 免疫グロブリン(ヒト)-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • NOE-105-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • セプラノロン-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • 中枢神経系障害およびホルモン障害に対してDRD2に拮抗する小分子-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • トゥレット症候群-休眠プロジェクト
  • トゥレット症候群-製造中止製品
  • トゥレット症候群-製品開発のマイルストーン
  • 注目のニュースとプレスリリース
  • 2021年2月11日:新しい前臨床試験によるセプラノロンがトゥレット症候群のチックを抑制することの確認
  • 2020年9月1日:EmalexBiosciencesのフェーズ2bトゥレット症候群の臨床試験の登録がマイルストーンに到達
  • 2020年3月24日:AsarinaPharmaによる過去のフェーズ2bPMDDデータのスケジュールどおりのリリース
  • 2020年2月20日:Tevaのデュテトラベナジンが小児トゥレット症候群の臨床試験に失敗
  • 2019年8月28日:Emalex Biosciencesのトゥレット症候群患者の治療のためのエコピパムのFDAファストトラック指定取得
  • 2019年8月14日:Emalex Biosciencesによるトゥレット症候群の小児患者の治療におけるエコピパム錠の有効性と安全性を評価するためのフェーズ2臨床試験に登録された最初の患者の発表
  • 2019年8月6日:EmalexBiosciencesがDr.Atul R.Mahableshwarkarを医薬品開発担当上級副社長に任命
  • 2018年6月11日:Therapix Biosciencesのトゥレット症候群研究のための欧州学会の2018年年次総会の後援
  • 2018年4月9日:Therapix Biosciencesによるイェール大学でのトゥレット症候群プログラムに関するフェーズ2a臨床試験のトップライン結果の発表
  • 2018年2月28日:Nuvelution Pharmaによる小児患者のトゥレット症候群の治療を目的としたAUSTEDO(R)(デュテトラベナジン)のフェーズ2/3臨床試験への患者登録開始の発表
  • 2018年2月7日:Therapix Biosciencesのトゥレット症候群のTHX-110に関するFDAとのプレINDコミュニケーションの完了:臨床開発の計画どおりの進行
  • 2017年12月4日:Therapix Biosciencesは、トゥレット症候群プログラムのためのイェール大学でのフェーズ2a研究の登録完了の発表
  • 2017年10月11日:Nippon ChemipharとSOM Biotechによるベバントロール(カルバン)の新しい希少疾患の適応症への協力
  • 2017年5月8日:TherapixBiosciencesとHannover Medical Schoolによるトゥレット症候群患者におけるTXH-TS01の効果を評価するための治験責任医師が開始した臨床試験契約の締結
  • 2017年1月17日:Psyadonの小児トゥレット症候群治療のためのエコピパムのフェーズ2臨床試験からの肯定的な結果の発表
  • 付録
  • 調査手法
  • 調査範囲
  • 2次調査
  • 1次調査
  • エキスパートパネルの検証
  • お問い合わせ
  • 免責事項
図表

List of Tables

  • Number of Products under Development for Tourette Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tourette Syndrome - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
  • Tourette Syndrome - Pipeline by Asarina Pharma AB, 2021
  • Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2021
  • Tourette Syndrome - Pipeline by Evero Health Ltd, 2021
  • Tourette Syndrome - Pipeline by Noema Pharma AG, 2021
  • Tourette Syndrome - Pipeline by Octapharma AG, 2021
  • Tourette Syndrome - Pipeline by SOM Biotech SL, 2021
  • Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Tourette Syndrome - Dormant Projects, 2021
  • Tourette Syndrome - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Tourette Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC12768IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Tourette Syndrome - Overview
  • Tourette Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tourette Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tourette Syndrome - Companies Involved in Therapeutics Development
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • Tourette Syndrome - Drug Profiles
  • alpha-dihydrotetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevantolol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • deutetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dronabinol + palmidrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ecopipam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOE-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sepranolone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tourette Syndrome - Dormant Projects
  • Tourette Syndrome - Discontinued Products
  • Tourette Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
  • Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
  • Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
  • Feb 20, 2020: Teva's deutetrabenazine fails in paediatric Tourette syndrome trials
  • Aug 28, 2019: Emalex Biosciences receives FDA Fast Track Designation for Ecopipam for the treatment of patients with Tourette Syndrome
  • Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome
  • Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
  • Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
  • Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
  • Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette Syndrome in Pediatric Patients
  • Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
  • Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
  • Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
  • May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
  • Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer